-
Mashup Score: 0ASTRO 2023: Exploring the Potential for SBRT - 7 month(s) ago
Martin King, MD, PhD, offers insights on SBRT’s potential to redefine treatment in prostate and renal cancer.
Source: www.medscape.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0COSMIC-313: Investigating Progression-Free Survival Benefits in Renal Cancer Therapy - Toni K. Choueiri - 7 month(s) ago
Alicia Morgans and Toni Choueiri discuss the findings of the COSMIC-313 study, as published in the New England Journal of Medicine. The study examines the efficacy of adding cabozantinib to the Nivolumab-Ipilimumab (NIVO-IPI) regimen for treating advanced renal cell carcinoma. It finds that the triple combination (NIVO-IPI-CABO) significantly improves progression-free survival, especially in…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Unlocking insights in #RenalCancer therapy! 🌟 #WatchNow @DrChoueiri @DanaFarber and @CaPsurvivorship in this captivating discussion on investigating PFS benefits in renal cancer through #COSMIC313. Discover potential advancements in treating renal cancer! https://t.co/Fje7N4zvi0 https://t.co/xUPwvuODBV
-
-
Mashup Score: 2COSMIC-313: Investigating Progression-Free Survival Benefits in Renal Cancer Therapy - Toni K. Choueiri - 8 month(s) ago
Alicia Morgans and Toni Choueiri discuss the findings of the COSMIC-313 study, as published in the New England Journal of Medicine. The study examines the efficacy of adding cabozantinib to the Nivolumab-Ipilimumab (NIVO-IPI) regimen for treating advanced renal cell carcinoma. It finds that the triple combination (NIVO-IPI-CABO) significantly improves progression-free survival, especially in…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Unlocking insights in #RenalCancer therapy! 🌟 #WatchNow @DrChoueiri @DanaFarber and @CaPsurvivorship in this captivating discussion on investigating PFS benefits in renal cancer through #COSMIC313. Discover potential advancements in treating renal cancer! https://t.co/Fje7N4zvi0 https://t.co/Fc8jCzM3f2
-
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Patients with sarcomatoid and/or rhabdoid metastatic non-clear cell renal cell carcinoma are known to have poor clinical outcomes. Studies found potential benefits of immunotherapy-based regimens for this patient population: https://t.co/36Ffv4hNfm #RenalCancer #Carcinoma #ASCO https://t.co/m64AjfhW3z
-
-
Mashup Score: 0
Renal Cell Carcinoma (RCC), Lymph node dissection, Nephrectomy, Lymph Nodal Metastases in Patients with Renal Cancer, Neglected Lymph Nodal Metastases in Patients with Renal Cancer, Anatomical Template of Lymph Node Dissection During Nephrectomy, Radical Nephrectomy (RN), Partial Nephrectomy (PN).
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Neglected lymph nodal metastases in patients with #RenalCancer: When to extend the anatomical template of lymph node dissection during nephrectomy. #BeyondTheAbstract with Pietro Scilipoti and Giuseppe Rosiello @SanRaffaeleMI > https://t.co/YYx5TCqVgz @wjurol https://t.co/5ZESPi1x3E
-
-
Mashup Score: 0The Changing Landscape of Immunotherapy for Advanced Renal Cancer - Beyond the Abstract - 10 month(s) ago
Advanced Renal Cancer, renal cell carcinoma (RCC), VEGF receptor, tyrosine kinase inhibitors (TKI), KEYNOTE–426 trial, JAVELIN Renal 101 trial, pembrolizumab plus lenvatinib, CLEAR trial, nivolumab plus cabozantinib, CheckMate 9ER study, novel immune checkpoints, ImMotion010 trial, PROSPER study, COSMIC-313 study, MK–6482–012 trial, PDIGREE.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
The changing landscape of immunotherapy for advanced #RenalCancer. #BeyondTheAbstract with @KashimaMDPhD and @BraunMDPhD @YaleCancer. #ReadNow on UroToday > https://t.co/uxcobYHIXM @YaleMed @UrologicClinics https://t.co/hexZFDv27g
-
-
Mashup Score: 0‎EAU - Urology - 11 month(s) ago
‎This the European Association of Urology’s official app! Use it to stay informed on the latest news, manage your membership and find out more about the Association’s activities. This is also the way to access virtual events on your mobile devices! When you attend the EAU’s Annual Congress or other m…
Source: App StoreCategories: Latest Headlines, UrologyTweet-
💥The #UROonco23 App is now live and ready for you to use! It is free to access via the EAU App 👉Download the app on the App Store (https://t.co/pKzbNuFDqB) or Google Play (https://t.co/xsJQ6ULLfg) #ProstateCancer, #BladderCancer, #RenalCancer #ESOU https://t.co/8GYfksmhPs
-
-
Mashup Score: 0Immunotherapeutics 2023 | EUSTM Virtual Congress - 1 year(s) ago
From Biology to Patients Care
Categories: Latest Headlines, Oncologists2Tweet-
If interested in contemporary #prognostic models for #immunotherapy based on #blood #inflammatory indexes for #lungcancer #mesothelioma #renalcancer #bladdercancer join streaming and on delay #Immunotherapeutics2023 from 07.05.23 9.00am CET time https://t.co/OeMJuIVzDK https://t.co/qFyXssZlUj
-
-
Mashup Score: 0Durvalumab Alone or with Savolitinib or Tremelimumab in Previously Treated Advanced Clear Cell Renal Cancer - CALYPSO Trial Results - Tom Powles - 1 year(s) ago
Thomas Powles discusses the results of the CALYPSO trial with Pedro Barata. Dr. Powles provides an overview of the trial design of this international, multicentre, open-label phase Ib/IIa study of durvalumab alone, savolitinib alone, and durvalumab in combination with savolitinib or tremelimumab in patients with metastatic renal cell cancer. He then discusses the trial results, plus his…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell #RenalCancer - #CALYPSO trial results. @tompowles1 @QMBCI joins @PBarataMD @caseccc joins in this discussion on UroToday > https://t.co/3Bv8mHHhV0 https://t.co/tBEkqcUniQ
-
-
Mashup Score: 0Durvalumab Alone or with Savolitinib or Tremelimumab in Previously Treated Advanced Clear Cell Renal Cancer - CALYPSO Trial Results - Tom Powles - 1 year(s) ago
Thomas Powles discusses the results of the CALYPSO trial with Pedro Barata. Dr. Powles provides an overview of the trial design of this international, multicentre, open-label phase Ib/IIa study of durvalumab alone, savolitinib alone, and durvalumab in combination with savolitinib or tremelimumab in patients with metastatic renal cell cancer. He then discusses the trial results, plus his…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell #RenalCancer - #CALYPSO trial results. @tompowles1 @QMBCI joins @PBarataMD @caseccc joins in this discussion on UroToday > https://t.co/3Bv8mHHPKy https://t.co/ZBsZS8afgy
-
📽️ Martin King, MD, PhD, offers insights on SBRT's potential to redefine treatment in prostate and #renalcancer. #ASTRO23 #OncTwitter #RadiationTherapy #ProstateCancer https://t.co/lSWpLsm1LT https://t.co/CAoEUlbGeN